Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
APGE 
Apogee Therapeutics, Inc. Common Stock (APGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: APGE (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $97.88
1 Year Target Price $97.88
| 9 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.38% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.20B USD | Price to earnings Ratio - | 1Y Target Price 97.88 |
Price to earnings Ratio - | 1Y Target Price 97.88 | ||
Volume (30-day avg) 9 | Beta 1.43 | 52 Weeks Range 26.20 - 63.50 | Updated Date 09/17/2025 |
52 Weeks Range 26.20 - 63.50 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -23.21% | Return on Equity (TTM) -34.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1700956707 | Price to Sales(TTM) - |
Enterprise Value 1700956707 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 46109800 | Shares Floating 37775573 |
Shares Outstanding 46109800 | Shares Floating 37775573 | ||
Percent Insiders 7.59 | Percent Institutions 132.45 |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics, Inc. is a biotechnology company focused on developing novel biologics for the treatment of inflammatory and immunological diseases. Founded in 2022, they are relatively new and are focused on rapid development programs for biologics targeting validated pathways. The company is based in Waltham, Massachusetts.
Core Business Areas
- Antibody Therapeutics Development: Apogee develops differentiated biologics for immunology and inflammatory diseases, aiming to improve treatment outcomes for patients.
- Clinical Trials: Apogee is actively involved in conducting clinical trials to evaluate the safety and efficacy of their therapeutic candidates.
Leadership and Structure
The leadership team includes experienced professionals in drug development and biotechnology. The company's structure is typical of a biotech company, with departments focused on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- APG777: APG777 is an anti-IL-23 antibody in Phase 1 clinical trials for inflammatory bowel disease (IBD). Market share is yet to be determined as product is still in development. Competitors include JNJ (Tremfya) and ABBV (Skyrizi).
- APG808: APG808 is an anti-IL-4Ru03b1 antibody in preclinical development for atopic dermatitis. Market share is yet to be determined as product is still in development. Competitors include SNY (Dupixent).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing significant growth, driven by advancements in genomics, proteomics, and drug delivery technologies. The market for inflammatory and immunological disease therapies is substantial and growing.
Positioning
Apogee Therapeutics, Inc. is positioned as a developer of novel biologics targeting established inflammatory and immunological pathways. Their competitive advantage lies in their focus on creating differentiated therapies with potentially improved efficacy and safety profiles.
Total Addressable Market (TAM)
The TAM for inflammatory and immunological disease therapies is estimated to be in the tens of billions of dollars annually. Apogee is positioning itself to capture a share of this market with its novel therapies targeting validated pathways.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Novel therapeutic candidates
- Focus on validated pathways
- Strong financial backing
Weaknesses
- Early stage of development
- Reliance on clinical trial success
- Limited product portfolio
- No approved products currently
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of product portfolio
- Acquisition of complementary technologies
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- SNY
Competitive Landscape
Apogee faces competition from established pharmaceutical companies with approved therapies. Its competitive advantage lies in its potentially differentiated biologics targeting validated pathways.
Growth Trajectory and Initiatives
Historical Growth: Since its recent founding, Apogee's growth is based on its R&D pipeline progress and funding.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization strategies. Analyst estimates are based on the potential of their product pipeline.
Recent Initiatives: Recent initiatives include advancing APG777 into Phase 1 clinical trials, progressing APG808 in preclinical development, and securing funding.
Summary
Apogee Therapeutics is a young biotech firm focusing on inflammatory and immunological diseases. Its strength lies in its experienced team and novel therapeutic candidates, but it faces challenges due to its early stage of development and competition from established players. Successful clinical trials and strategic partnerships are crucial for its growth, while regulatory hurdles and potential clinical failures pose significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Apogee Therapeutics, Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is approximate and may vary based on different sources. Financial data is based on publicly available information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 | |||
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.